These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33382581)

  • 1. Pyridine-2,6-dicarboxaldehyde-Enabled N-Terminal In Situ Growth of Polymer-Interferon α Conjugates with Significantly Improved Pharmacokinetics and In Vivo Bioactivity.
    Sun J; Liu X; Guo J; Zhao W; Gao W
    ACS Appl Mater Interfaces; 2021 Jan; 13(1):88-96. PubMed ID: 33382581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In situ growth of a C-terminal interferon-alpha conjugate of a phospholipid polymer that outperforms PEGASYS in cancer therapy.
    Hu J; Wang G; Zhao W; Gao W
    J Control Release; 2016 Sep; 237():71-7. PubMed ID: 27393654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Site-specific in situ growth of an interferon-polymer conjugate that outperforms PEGASYS in cancer therapy.
    Hu J; Wang G; Zhao W; Liu X; Zhang L; Gao W
    Biomaterials; 2016 Jul; 96():84-92. PubMed ID: 27152679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymerization Induced Self-Assembly of a Site-Specific Interferon α-Block Copolymer Conjugate into Micelles with Remarkably Enhanced Pharmacology.
    Liu X; Sun M; Sun J; Hu J; Wang Z; Guo J; Gao W
    J Am Chem Soc; 2018 Aug; 140(33):10435-10438. PubMed ID: 30084632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conjugation of PolyPEG to interferon alpha extends serum half-life while maintaining low viscosity of the conjugate.
    Podobnik B; Helk B; Smilović V; Škrajnar Š; Fidler K; Jevševar S; Godwin A; Williams P
    Bioconjug Chem; 2015 Mar; 26(3):452-9. PubMed ID: 25629733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
    García-García I; González-Delgado CA; Valenzuela-Silva CM; Díaz-Machado A; Cruz-Díaz M; Nodarse-Cuní H; Pérez-Pérez O; Bermúdez-Badell CH; Ferrero-Bibilonia J; Páez-Meireles R; Bello-Rivero I; Castro-Odio FR; López-Saura PA;
    BMC Pharmacol; 2010 Nov; 10():15. PubMed ID: 21092287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and biologic characterization of pegylated recombinant IFN-alpha2b.
    Grace M; Youngster S; Gitlin G; Sydor W; Xie L; Westreich L; Jacobs S; Brassard D; Bausch J; Bordens R
    J Interferon Cytokine Res; 2001 Dec; 21(12):1103-15. PubMed ID: 11798469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.
    Rosendahl MS; Doherty DH; Smith DJ; Carlson SJ; Chlipala EA; Cox GN
    Bioconjug Chem; 2005; 16(1):200-7. PubMed ID: 15656592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative.
    Ramon J; Saez V; Baez R; Aldana R; Hardy E
    Pharm Res; 2005 Aug; 22(8):1374-86. PubMed ID: 16078148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pegylated interferons: pharmacological basis].
    Macquin-Mavier I; Hezode C; Dhumeaux D
    Gastroenterol Clin Biol; 2002; 26(8-9):742-7. PubMed ID: 12434079
    [No Abstract]   [Full Text] [Related]  

  • 11. Site-Specific Transglutaminase-Mediated Conjugation of Interferon α-2b at Glutamine or Lysine Residues.
    Spolaore B; Raboni S; Satwekar AA; Grigoletto A; Mero A; Montagner IM; Rosato A; Pasut G; Fontana A
    Bioconjug Chem; 2016 Nov; 27(11):2695-2706. PubMed ID: 27731976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.
    Jo YW; Youn YS; Lee SH; Kim BM; Kang SH; Yoo M; Choi EC; Lee KC
    Int J Pharm; 2006 Feb; 309(1-2):87-93. PubMed ID: 16406701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In situ growth of a stoichiometric PEG-like conjugate at a protein's N-terminus with significantly improved pharmacokinetics.
    Gao W; Liu W; Mackay JA; Zalutsky MR; Toone EJ; Chilkoti A
    Proc Natl Acad Sci U S A; 2009 Sep; 106(36):15231-6. PubMed ID: 19706892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Site-specific in situ growth of a cyclized protein-polymer conjugate with improved stability and tumor retention.
    Hu J; Zhao W; Gao Y; Sun M; Wei Y; Deng H; Gao W
    Biomaterials; 2015 Apr; 47():13-9. PubMed ID: 25682156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled Radical Polymerization as an Enabling Approach for the Next Generation of Protein-Polymer Conjugates.
    Pelegri-O'Day EM; Maynard HD
    Acc Chem Res; 2016 Sep; 49(9):1777-85. PubMed ID: 27588677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
    Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Interferon alpha-2b modified with polyethylene glycol].
    Wu Y; Zhai Y; Lei J; Ma G; Su Z
    Sheng Wu Gong Cheng Xue Bao; 2008 Sep; 24(9):1658-63. PubMed ID: 19160853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of pegylated interferons: what is misleading?
    Caliceti P
    Dig Liver Dis; 2004 Nov; 36 Suppl 3():S334-9. PubMed ID: 15645663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs.
    Cai Y; Zhang Z; Fan K; Zhang J; Shen W; Li M; Si D; Luo H; Zeng Y; Fu P; Liu C
    Regul Pept; 2012 Jan; 173(1-3):74-81. PubMed ID: 21985916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
    Baker DP; Lin EY; Lin K; Pellegrini M; Petter RC; Chen LL; Arduini RM; Brickelmaier M; Wen D; Hess DM; Chen L; Grant D; Whitty A; Gill A; Lindner DJ; Pepinsky RB
    Bioconjug Chem; 2006; 17(1):179-88. PubMed ID: 16417267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.